Article Text

Download PDFPDF
Hormone replacement therapy was associated with increased venous thromboembolism and deep venous thrombosis

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In women with coronary artery disease, does hormone replacement therapy (HRT) (oestrogen plus progestin) increase the risk for venous thromboembolism (VTE)?


Randomised (unclear allocation concealment*), blinded (patients, investigators, and outcome assessors),* placebo controlled trial with a mean follow up of 4.1 years (Heart and Estrogen/progestin Replacement Study [HERS]).


20 US outpatient and community settings.


2763 postmenopausal women between 44 and 79 years of age (mean age 67 y, 89% white) who had established coronary artery disease and who had not had a hysterectomy. Exclusion criteria were recent coronary events; recent use of hormone therapy; history of VTE, breast cancer, or endometrial cancer; uncontrolled hypertension; diabetes; or other life …

View Full Text


  • Source of funding: Wyeth-Ayerst Laboratories.

  • For correspondence: Dr D Grady, University of California, San Francisco, 74 New Montgomery Street, Suite 600, San Francisco, CA 94105, USA. Fax +1 415 386 4044.

  • A modified version of this abstract also appears in Evidence-Based Nursing.

  • * See glossary.